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East African Trypanosomiasis in Nkhotakota District 
M Delbaere, JB Matengele 
A marked increase in trypanosomiasis has been 
seen at Nkhotakota District Hospital since Sep-
tember 1989. This report presents background 
information, the extent of the recent outbreak 
and a suggested revised treatment protocol. Sug-
gestions are made for preventative measures 
against the spread of trypanosomiasis. 
Introduction 
East Mrican Trypanosomiasis (sleeping sick-
ness) is seen in East and Central Mrica and is 
caused by the parasite Trypanosoma brucei rhode-
siense. West Mrican Trypanosomiasis is caused by 
Trypanosoma brucei gamhiense and is not seen in 
Malawi. WHO statistics for the period 1976 -1983, 
estimated that out of a total population of 6.4 
million in Malawi there were 1.2 million people at 
risk of infection with T. h. rhodesiense 1. Total re-
ported cases of trypanosomiasis for Malawi are 
shown in the Table. 
Table Reported cases o/trypanosomiasis in Malawi /mm two 
data sOU"ces (197J - 1984) 
YEARS 
73 74 75 76 77 78 79 80 81 82 83 84 
SOURCE 
13 32 27 7 38 18 
14 8 13 32 32 28 23 21 17 - 55 
1 
2 
Epidemiology of trypanosomiasis in Nkhotakota 
MORBIDfIY AND MORTALfIY: In Nkhota-
kota there were 2 cases re-
ported in 1973, 1 case in 
1979 and 1 case in 1980 2• 
However from 1989 there 
was a marked increase in 
cases seen: 21 cases for 
1989, 209 cases for 1990 
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I Confirmed caaea 
Deaths 
and 64 cases for the first two months of 1991 
(Nkhotakota District Hospital statistics). This data 
is shown in further detail in Figure 1. Since the 
beginning of 1991 more than 1 patient suffering 
from trypanosomiasis has been admitted every day. 
Patients with trypanosomiasis were classified as 
being either early or late stage. The "early" stage is 
were the disease has not affected the central nerv-
ous system (CNS), whereas the "late" stage is when 
CNS spread has occurred. A lumber puncture is 
done to "confirm" the presence or absence of try-
panosomes in the CNS. 
During the period of the study there were 61 
patients "confirmed early stage", 55 patients "sus-
pected early stage", 24 patients "confirmed late 
stage" and 29 patients "suspected late stage". Over-
all there were 116 (69%) in the early stage (sus-
pected or confirmed) and 53 (31 %) in the late stage 
(suspected or confirmed). A further 40 patients 
were classified as stage unknown. In 1990 there 
were 152 (73%) male and 57 (27%) female ad-
missions with trypanosomiasis. The age and sex 
distribution is shown in Figure 2. 
The mortality rate of trypanosomiasis is 100% in 
the untreated patient. In the advanced late stage of 
the disease the prognosis is poor though treatment 
is not hopeless. In 1990 trypanosomiasis accounted 
for 11 % of all hospital deaths. Needless to say many 
deaths will occur in the villages in tsetse infested 
areas. 
The extent of the disease in the community is 
not known. There is no organised active case detec-
tion established in the villages within the tsetse 
infested area. Probably the hospital based figures 
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represent the tip of the iceberg. The disease is 
associated with a great deal of suffering and misery 
to both the patient and family, especially in late 
stage. 
101 
from the estates close to the Nkhotakota Game 
Reserve boundary. Occasional unsuspected spread 
may also occur e.g. a stranded bus (due to a break-
down) was seen adjacent to the Game Reserve with 
NKHOTAKOTA TRYPANOSOMIASIS - 1990 
AGE AND SEX DISTRIBUTION 
at least 40 - 50 people 
waiting until the prob-
lem was solved. 
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Years 
Most of the patients 
with trypanosomiasis 
admitted to Nkhota-
kota District Hospital 
or seen as outpatients 
come from certain 
areas: T.A. Malenga-
chanzi (79) and STA 
Mphonde (70), T.A. 
Mwadzama (14) and 
STA 'Mwansambo (8). 
Villages which are seri-
ously affected are 
~Male ~Female 
Figure 2 RHO(C) 3011/81 8ouroe:DHO Nkhotamta 
GEOGRAPHIC DISTRIBUTION: The spread of 
trypanosomiasis depends on the host-vector-para-
site relationship. In an endemic situation "game-fiy-
man" cycle predominates whilst in an epidemic 
situation (as seen in Nkhotakota) "man-fiy-man" 
and "domestic animal-fiy-man" cycles predominate. 
Domestic animals that can serve as reservoir hosts 
include cattle, sheep, goats and dogs. 
The game hosts that have been identified as 
reservoirs are the bushbuck (which is perhaps the 




Nkhongo and others, 
situated along Nkhotakota Game Reserve. There 
have been 2 patients from Ntchisi District and 2 
from Kasungu DistricL 
Clinical and laboratory diagnosis 
CUNICAL PRESENTATION: It is not possible to 
make a diagnosis of trypanosomiasis on clinical 
manifestations alone and only parasitological 
examination will confirm the diagnosis. There are 
certain symptoms which suggest the diagnosis espe-
cially when they occur in combination. There is a 
thog, hyena and 
hartebest. All 
these animals are 
found in Nkhota-
kota game reserve. 
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difference between West Mrican trypanosomiasis 
(T. b. gambiense) and East Mrican trypanosomiasis 
(T. b. rhodesiense). Symptoms of the latter are more 
severe and acute. 
Trypanosomiasis caused by T. b. rhodesiense has 
an incubation period of 1 - 3 weeks. The most 
common signs and symptoms are fever, headache, 
general body weakness, leg oedema, splenomegaly, 
cervical lymphadenopathy and in the advanced 
stage of the disease there is confusion, convulsions, 
neck stiffness and drowsiness (i.e. a range from 
"decreased level of consciousness" to coma). These 
clinical features according to the stage of the dis-
ease are shown in Figure 3. 
Trypanosomiasis can thus present a diagnostic 
problem in view of the wide possible differential 
diagnosis, especially when the blood-filr~ is nega-
tive. Many infections have been misdiagnosed as 
malaria (certainly in children), typhoid fever and 
hepatitis. Lymphadenopathy with fever in a wasted 
patient must be differentiated from HIV infection 
or tuberculosis. Trypanosomiasis may be confused 
with congestive cardiac failure, nephrotic syn-
drome or even malnutrition. In the advanced stage 
of the disease it must be differentiated from cere-
bral malaria and meningitis. The diagnosis may be 
masked when combined with other pathology e.g. 
patients have been seen with HIV infection and 
trypanosomiasis, and a child with bacterial mening-
itis and trypanosomiasis. 
LABORATORY DIAGNOSIS: The diagnostic 
methods used in Nkhotakota District Hospital la-
boratory, are a blood-film (Field stain) for parasite 
detection, a direct cerebrospinal fluid (CSF) exam-
ination for parasite detection and white blood cell 
count and differential. Concentration techniques 
by centrifugation were not done due to lack of 
equipment and materials. Elevations in protein 
level in the CSF are detected with urine protein 
sticks since there are no materials to perform a 
flocculation reaction or the method of Sicard and 
Cantaloube. 
The single laboratory assistant, besides perfor-
ming all other diagnostic tests for the hospital, has 
little time to go through all the fields per slide to 
pick up the parasites in so many slides every day. 
The disease cannot be confidently excluded on the 
basis of a single negative blood film only. 
Treatment of East African Trypanosomiasis 
The choice and schedule of treatment depend 
on the stage of the disease. As already men-
tioned, the CSF results, though not completely 
satisfactory, will be a guide to what treatment 
should be given. 
Suramin (an ureum derivative) is used for early 
Mela.wi Medicel Journal. December 1991. Vol 7. No. 3 
stage trypanosomiasis. A combined course of Su-
ramin and Melarsoprol (an arsenic derivative) will 
treat late stage patients. 
The supply of both Suramin and Melarsoprol is 
erratic. Between November 1989 andJune 1990 a 
large proportion of our patients were discharged 
without treatment or with partial treatment, only 
to die later in the villages. 
The two drugs, besides having a curative effect, 
are potentially toxic to the patient. Reactive ence-
phalopathy from Melarsoprol probably accounts 
for 5% of all deaths in patients who have the late 
stage of the disease 1. 
Broad guidelines for treatment have been pub-
lished by the WHO expert Committee on Trypan-
osomiasis, but they do not give preference for any 
treatment scheme. We have followed an abbrevi-
ated course of treatment which has been used at 
Kamuzu Central Hospital (Table 1). The results of 
using this treatment at Nkhotakota District Hospi-
tal during 1990 are summarised. 
Suramin treatment alone: 56 patients had an in-
terrupted course due to drug shortage (50) or 
because patients absconded (6). 64 patients re-
ceived a full course of Suramin and most of them 
improved. 11 patients died (7 arrived in very bad 
condition and during treatment developed fever 
and died - presumably late stage). 4 patients de-
veloped high fever and died (2 of these patients had 
coma). 1 patient died 2 months after an interrupted 
course of Suramin. 
Reactions to Suramin were noted in a few pa-
tients: fever (6) and diarrhoea (6). One lady, who 
became hysterical on the 4th day of Suramin treat-
ment and had diarr)1oea and convulsions, re-
covered fully. .,: l 
Suramin and Melarsoprol Treatment: There were 
10 patients with negative CSF results but with clini-
cal late stage disease. They all improved clinically, 
but 1 patient had residual brain damage, 1 patient 
had diarrhoea during the course and 1 patient had 
a reactive encephalitis (the family wanted to take 
the patient home in this bad condition). 
There were 17 patients confirmed late stage 
disease (trypanosomes identified in the CSF). 1 
patient had previously had a negative CSF examin-
ation. They all improved, except 1 child who de-
veloped reactive encephalitis and hepatitis 
(possibly drug induced). The child was taken home 
with severe brain damage and died later in the 
village. 
There were an additional 3 patients who arrived 
in a very bad condition. The first patient received 
the first series of Melarsoprol injections and de-
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patient, who was also HIV reactive, died after the 
Melarsoprol course. The third patient died after 2 
doses of Melarsoprol, probably due to reactive 
encephalitis. 
Comments on this treatment: Following this 6 
months experience in treating trypanosomiasis, 
and after consulting all available literature on the 
subject, a modified treatment protocol is proposed. 
(Table 2). 
Some doctors, with many years experience treat-
ing T. b. gambiense infection in Zaire, claim that the 
trypanosomes are alreadrrsresent in the CNS even 
without changes in CSF .. 5. These trypanosomes 
may be responsible for relapses seen after the clas-
sic treatment schemes. They therefore administer 
1 series (3 days) ofMelarsoprol (at full dosage) after 
Suramin treatment in "early stage" trypanoso-
miasis. Adopting this treatment policy would also 
seem reasonable in our setting since T. b. rhodesiense 
invades the CNS relatively early. Further arguments 
in support of this approach is the difficulty in 
following up patients (theoretically should be at 3, 
6, 12 and 24 months after treatment), and the fact 
that our laboratory detection methods for CSF 
changes are not that reliable. We believe that sev-
eral patients with early central nervous system in-
volvement were missed. These patients may then 
die in the village. 
We believe that 4 doses of Suramin before giving 
Melarsoprol in late stage disease is too many. In 
Kenya and Zambia 3 doses are given, and in Tanza-
nia and Uganda only 2 doses are given. The interval 
before starting Melarsoprol should only be 1 day 
instead of 1 week. These modifications will save 
drugs, shorten the hospital stay and do not appear 
to affect outcome. 
In Malawi Melarsoprol haSbeen administered in 
a dextrose solution, whereas in surveys of other 
countries it is given IV STAT. We have therefore 
started giving Melarsoprol IV STAT. Earlyexperi-
ence after 4 weeks has shown good results and no 
adverse reactions. 
Cost of Hospital Treatment: We expect the 
epidemic to increase during 1991 (so far January 
34 patients, and February 34 patients). We expect 
to see 30 patients per month during 1991 (20 in 
early stage, and 10 in late stage of the disease). 
Using the modified treatment scheme shown in 
Table 2, we would need 140 vials of Suramin, 180 
ampoules Melarsoprol, 140 IV giving sets, 140 litres 
of 5% Dextrose, 2050 tablets Prednisolone (5 mg) 
and 60 urine sticks (protein). Calculations based on 
Malawi Central Medical Stores prices show a 
monthly cost for 30 patients of K 17,426 and a 
yearly cost of K 209,113. Even excluding the very 
103 
expensive Suramin and Melarsoprol the monthly 
expenses for 30 patients will still be K 2,006 and a 
yearly cost of K 24,074. The latter represents 15% 
of the 1990 Drug Budget for Nkhotakota District 
Hospital. Other effects not easily cos ted are: in-
creased nursing workload; higher bed-occupancy; 
extra food for patients; and a heavy laboratory 
workload (blood-film, CSF examinations, and urine 
examinations ). 
A donation of drugs from the EEC will last till 
March 1991. The Belgian Government has pro-
vided Melarsoprol, and it is hoped that other do-
nors will help in the future with treatment as well 
as screening and prevention. 
Prevention of Trypanosomiasis 
With the rapid population growth, land which 
was previously allocated as "Reserves" (close to the 
boundary of the Game Reserve) has now been 
released for settlement and agricultural use. How-
ever public concern is now to avoid or even aban-
don these tsetse fly infested areas. 
In the control of disease there has been progress 
in collecting baseline data on the tsetse fly popula-
tion and their behaviour, which is necessary to draw 
up a strategy for vector control. However medical 
surveillance of the human population is virtually 
non- existent. So far the emphasis of the National 
Tsetse and Trypanosomiasis Control programme 
has been towards control of the disease in domestic 
and game animals and vector control. This pro-
gramme should be extended towards the control of 
the disease in the human population. Regular medi-
cal surveillance of the population at risk and mass 
treatment for those infected (coupled with vector 
control) is the only hope for controlling the disease 
in Nkhotakota. Given the present precarious 
situation we wonder whether we should be using 
limited resources to trea! patients who will return 
to the same environment only to be re-infected. 
Unless there is a combined response from the 
medical surveillance and vector control sectors, 
we will never be successful in our hospital treat-
ment. 
A comprehensive situation analysis is required. 
Information is needed on the prevalence and 
spread of trypanosomiasis; demographic data on 
the population at risk; information on the vegeta-
tion of the area with emphasis on demand for land 
and food; future development in the district e.g. 
the proposed expansion of the Dwangwa Sugar 
plantation and the construction of the road from 
Kasungu to Nkhotakota; prediction on population 
growth; information on potential vector and ani-
mal reservoirs. 
Prevention can be achieved by a combination of 









































riers/cases (both actively and passively) 
and treatment of all patients infected is 
needed to break the transmission cycle 
(man-fiy-man). This will require a suffi-
cient stock of drugs. Resources for fol~ 
low-up will be needed as unfortunately 
some villagers abscond or do not co-
operate with treatment. Community 
awareness can be increased through 
health education. Primary health care 
based programmes should involve vil-
lagers and follow up of treated patients. 
Advising villagers to abandon their vil-
lages is not a solution since acquisition of 
alternative land is not feasible and survi-
val depends on having sufficient land for 
food production. Vector control is 
possible with the use of odour baited 
insecticide impregnated targets. In Zim-
babwe trials have shown that placing tar-
gets at a density of 4 per square km 
achieved more than 95% reduction of 
tsetse flies I. 
Conclusion 
Nkhotakota District is witnessing a re-
surgence of tsetse flies responsible for 
the transmission of trypanosomiasis. The 
expanding population and increased de-
mand for agriculture land has made this 
devastating disease a major communic-
able disease in this district. 
A combined approach of active medi-
cal surveillance to detect trypanoso-
miasis cases, treatment and education of 
those infected and vector control with 
"targets" is the only hope of reducing the 
spread of this major communkable dis-
ease in Nkhotakota. Given sound plan-
ning, organisation, and financial 
resources this should be possible. 
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Table 1 Treatment Chart Trypanosomiasis (Abbreviated Course Based 
On Schedule Used At Kamuzu Central Hospital) 
If any reaction to the drug is observed (exfoliative der-
matitis, rash or reactive encephalitis) STOP TREATMENT 
and immediately inform the Clinical Officer. 
DAY OF EXAM EARLY STAGE LATE STAGE 
TREATMENT DRUG DRUG PREDNISOLONE 
0 Urine SURO.5G SUR 0.5 G 40mg 
1 Urine SUR l.0 G SUR l.0 G 40mg 
2 LP SUR l.OG SUR l.OG 40mg 
3 SUR l.OG SUR l.OG 40mg 
4 40mg 
5 40mg 
6 Urine 40mg 
7 SUR l.OG 40mg 
8 40mg 
9 40mg 
10 MELB5ml 40mg 
11 MELB5 ml 40mg 
12 MELB5 ml 40mg 
13 Urine 30mg 
14 SUR l.0 G 30mg 
15 - 19 30mg 
20 MELB5ml 25mg 
21 MELB5 ml 25mg 
22 MELB5ml 25mg 
23 -29 25mg 
30 MELB5 ml 
31 MELB5ml 








SURAMIN: must always be freshly prepared with sterile 
water for injection to a 10% solution. Dose for children is 20 
mg/kg. Adult (50 kg) = 1 G (1 vial maximum). Add to 200 
ml 5 % Dextrose and give over 2 hours. 
MELARSOPROL: Dose is STRICTLY 3.6 mg/kg. Adult 
dose 180 mg (one 5 ml ampoule). Dissolve in 200 ml 5% 
Dextrose and run over more than 2 hours. Avoid tissuing of 
the drug because it is highly irritant. 
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Table 2 New Treatment Scheme fOT Tlypanosomiasis 
If any reaction to the drug is observed (exfoliative dermatitis, 
rash or reactive encephalitis) STOP TREATMENT and imme-
diately inform the Clinical Officer. 
DAY OF EXAM EARLY STAGE LATE STAGE 
TREATMENT DRUG DRUG PREDNISOLONE 
0 Blood-film + Urine 
1 SUR 0.5 G SUR 0.5 G 40mg 
2 SUR 1.0 G SUR 1.0 G 40mg 
3 LP SUR 1.0 G 40mg 
4 SUR 1.0 G MELB 5 ml 40mg 
5 MEL B5ml 40mg 
6 MELB 5 ml 40mg 
7 Urine 40mg 
8 SUR LOG 40mg 
9 -13 40mg 
14 Urine MELB 5 011 30mg 
15 SUR LOG MEL 8 5 ml 3001g 
16 MELB5 ml MEL 85 ml 30mg 
17 MELB5ml 30mg 
18 MELB5 ml 3001g 
19 - 23 3001g 
24 MEL85 ml 2501g 
25 MELB5ml 25mg 
26 MELB 5 ml 25mg 
27 -33 25mg 
34 MELB5 ml 25mg 
35 MELB 5 ml 25mg 
36 MELB501l 25mg 
SURAMIN: must always be freshly prepared with sterile water 
for injection to a 10% solution. Dose for children is 20 mglkg. 
Adult (50 kg) = 1 G (1 vial maximum). Add to 200 ml 5 % 
Dextrose and give over 2 hours. 
MELARSOPROL: Dose is STRICTLY 3.6 mglkg. Adult dose 
180 mg (one 5 ml ampoule). Give as IV PUSH but take great 
care to avoid tissuing of the drug because it is highly irritant. 
PREDNISOLONE: Dose for children is 1 mglkg once daily. 
FOLLOW·UP: Review the patient for repeat blood film and 
lumbar puncture at 3, 6, 12, and 24 months post-treatment. 
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